Literature DB >> 10878081

Immunoglobulin A1 protease activity in Gemella haemolysans.

J A Lomholt1, M Kilian.   

Abstract

The purpose of this study was to determine the occurrence and nature of immunoglobulin A1 (IgA1) protease activity in members of the genus Gemella and related taxa. Among a total of 22 Gemella strains belonging to the four species Gemella haemolysans, Gemella morbillorum, Gemella sanguinis, and Gemella bergeriae and four reference strains of the species Helcococcus kunzii, Facklamia hominis, and Globicatella sanguinis, IgA1 protease activity was an exclusive character of all nine isolates of G. haemolysans. The IgA1 protease of G. haemolysans appears to be a metallo-type IgA1 protease that cleaves the Pro(227)-Thr(228) peptide bond in the hinge region of the alpha1 chain like that of several Streptococcus species. Phenotypic characterization of the isolates demonstrates that screening for IgA1 protease activity provides a valuable means for species differentiation in this group of bacteria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878081      PMCID: PMC87022     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Gemella bergeriae sp. nov., isolated from human clinical specimens.

Authors:  M D Collins; R A Hutson; E Falsen; B Sjöden; R R Facklam
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

2.  Phylogenetic relationship of Gemella morbillorum to Gemella haemolysans.

Authors:  A M Whitney; S P O'Connor
Journal:  Int J Syst Bacteriol       Date:  1993-10

Review 3.  Occurrence and nature of bacterial IgA proteases.

Authors:  M Kilian; B Thomsen; T E Petersen; H S Bleeg
Journal:  Ann N Y Acad Sci       Date:  1983-06-30       Impact factor: 5.691

Review 4.  The IgA1 proteases of pathogenic bacteria.

Authors:  A G Plaut
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

5.  Prevalence of Gemella haemolysans on the pharyngeal mucosa of man.

Authors:  U Berger
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

6.  Description of Gemella sanguinis sp. nov., isolated from human clinical specimens.

Authors:  M D Collins; R A Hutson; E Falsen; B Sjöden; R R Facklam
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 7.  Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence.

Authors:  M Kilian; J Reinholdt; H Lomholt; K Poulsen; E V Frandsen
Journal:  APMIS       Date:  1996-05       Impact factor: 3.205

Review 8.  Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci.

Authors:  R Facklam; J A Elliott
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  A comprehensive genetic study of streptococcal immunoglobulin A1 proteases: evidence for recombination within and between species.

Authors:  K Poulsen; J Reinholdt; C Jespersgaard; K Boye; T A Brown; M Hauge; M Kilian
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

10.  IgA1 proteases from Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, and Streptococcus sanguis: comparative immunochemical studies.

Authors:  M Kilian; J Mestecky; R Kulhavy; M Tomana; W T Butler
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

  10 in total
  2 in total

1.  Child saliva microbiota and caries: a randomized controlled maternal education trial in rural Uganda.

Authors:  Grace K M Muhoozi; Kelvin Li; Prudence Atukunda; Anne B Skaare; Tiril Willumsen; Morten Enersen; Ane C Westerberg; Alison Morris; Alexandre R Vieira; Per O Iversen; Barbara A Methé
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

2.  Gemella haemolysans Infection in Total Hip Arthroplasty.

Authors:  Barry Rose; Parminder J S Jeer; Anthony J Spriggins
Journal:  Case Rep Orthop       Date:  2012-05-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.